en · de · es · fr · pt
cjc-1295-notes.peptides5388.com › Info › Mechanism And Pharmacokinetics — 2026 Update

Mechanism And Pharmacokinetics — 2026 Update

By Editorial Desk · published 2026-01-26 · last reviewed 2026-02-24 · Info

Everything below concerns GHRH. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-02-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Identity and Naming History

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

Cjc-1295 at a glance

PropertyValueNotes
Target receptorGHRH receptor (GHRHR)Expressed on pituitary somatotrophs
Primary actionStimulates growth hormone releaseAmplifies pulse size
Half-life, albumin-binding formSeveral days as reportedSlow release from albumin complex
Half-life, unmodified analogAbout 30 minutes in animal estimatesCleared by proteases and filtration
Common analytical approachLC-MS/MS for peptide, immunoassay for hormonesMethods answer different questions

Albumin Binding and Duration of Action

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Related pages on this site

CJC-1295 Background and Mechanism

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

Further detail

Numerous events are hosted on the lawn at Bryant Park. Bryant Park Movie Nights, begun in the early 1990s, take place on Monday evenings during the summer. Various free musical performances are sponsored by corporations during months with warm weather, including Broadway in Bryant Park, sponsored by iHeartMedia and featuring performers from current Broadway musicals, integrated with content provided by event sponsors. The park has various activity areas open all day long, including board games, chess and backgammon, a putting green and Kubb area, an Art Cart, ping pong tables, and Petanque courts. The parks also offer free classes in juggling, yoga, tai chi, and knitting. In the 40th Street plaza of the park, there is a station called Bryant Park Games where visitors can borrow an array of games, including Chinese chess and quoits. In addition, chess and table tennis can also be played at Bryant Park. Food and drink are served at four park-operated concessionary kiosks. There are two additional kiosks on Fifth Avenue, bringing the total of concessionaires near Bryant Park to six.

== Disease relevance == Diseases have been linked to R5P imbalances in cells. Cancers and tumors show upregulated production of R5P correlated to increased RNA and DNA synthesis. Ribose 5-phosphate isomerase deficiency, the rarest disease in the world, is also linked to an imbalance of R5P. Although the molecular pathology of the disease is poorly understood, hypotheses included decreased RNA synthesis. Another disease linked to R5P is gout. Higher levels of G6P lead to a buildup of glycolytic intermediates, that are diverted to R5P production. R5P converts to PRPP, which forces an overproduction of purines, leading to uric acid build up. Accumulation of PRPP is found in Lesch-Nyhan Syndrome. The build up is caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which leads to decreased nucleotide synthesis and an increase of uric acid production. Superactivity in PRPS1, the enzyme that catalyzes the R5P to PRPP, has also been linked to gout, as well as neurodevelopmental impairment and sensorineural deafness.

=== Specific activity === The specific activity of an enzyme is another common unit. This is the activity of an enzyme per milligram of total protein (expressed in μmol min−1 mg−1). Specific activity gives a measurement of enzyme purity in the mixture. It is the micro moles of product formed by an enzyme in a given amount of time (minutes) under given conditions per milligram of total proteins. Specific activity is equal to the rate of reaction multiplied by the volume of reaction divided by the mass of total protein. The SI unit is katal/kg, but a more practical unit is μmol/(mg*min). Specific activity is a measure of enzyme processivity (the capability of enzyme to be processed), at a specific (usually saturating) substrate concentration, and is usually constant for a pure enzyme. An active site titration process can be done for the elimination of errors arising from differences in cultivation batches and/or misfolded enzyme and similar issues. This is a measure of the amount of active enzyme, calculated by e.g. titrating the amount of active sites present by employing an irreversible inhibitor. The specific activity should then be expressed as μmol min−1 mg−1 active enzyme. If the molecular weight of the enzyme is known, the turnover number, or μmol product per second per μmol of active enzyme, can be calculated from the specific activity. The turnover number can be visualized as the number of times each enzyme molecule carries out its catalytic cycle per second.

=== Medications that cause or worsen myasthenia gravis === Antibiotics: In the macrolide family of antibiotics, azithromycin, telithromycin (which is no longer available in the U.S. market), and erythromycin are reported to exacerbate myasthenia gravis. In the fluoroquinolone antibiotic family, ciprofloxacin, norfloxacin, ofloxacin, and moxifloxacin are reported to exacerbate myasthenia gravis. And, In the aminoglycoside family of antibiotics, gentamicin, streptomycin, and neomycin are reported to exacerbate myasthenia gravis. The aminoglycoside tobramycin has not been reported to exacerbate myasthenia gravis and may be used in people that require aminoglycoside treatment. Because of the rarity or absent reports on their exacerbation of myasthenia gravis, the following antibiotics are considered safe to use in people with myasthenia gravis: the cephalosporin class of drugs, sulfa drugs, the tetracycline group of drugs, clindamycin, polymyxin B, and nitrofurantoin. Immune checkpoint inhibitors: Immune checkpoint inhibitors promote certain types of autoimmune responses by blocking checkpoint pathways that inhibit these responses. They are used to treat cancers that promote their own growth and spread by stimulating checkpoint pathways. These checkpoint inhibitors include pembrolizumab, nivolumab, ipilimumab, avelumab, atezolizumab, and durvalumab. From a total 5,898 people who received these drugs, 52 developed new onset myasthenia gravis and 11 had a flare of their preexisting myasthenia gravis.

Sources: en.wikipedia.org

Supporting material

Walthard cell rests, sometimes called Walthard cell nests, are a benign cluster of epithelial cells most commonly found in the connective tissue of the fallopian tubes, but also seen in the mesovarium, mesosalpinx and ovarian hilus.

==== Direction of liquid pressure ==== An experimentally determined fact about liquid pressure is that it is exerted equally in all directions. If someone is submerged in water, no matter which way that person tilts their head, the person will feel the same amount of water pressure on their ears. Because a liquid can flow, this pressure is not only downward. Pressure is seen acting sideways when water spurts sideways from a leak in the side of an upright can. Pressure also acts upward, as demonstrated when someone tries to push a beach ball beneath the surface of the water. The bottom of a ball is pushed upward by water pressure (buoyancy). When a liquid presses against a surface, there is a net force that is perpendicular to the surface. Although pressure does not have a specific direction, force does. A submerged triangular block has water forced against each point from many directions, but components of the force that are not perpendicular to the surface cancel each other out, leaving only a net perpendicular point. This is why liquid particles' velocity only alters in a normal component after they are collided to the container's wall. Likewise, if the collision site is a hole, water spurting from the hole in a bucket initially exits the bucket in a direction at right angles to the surface of the bucket in which the hole is located. Then it curves downward due to gravity.

The genetic code expansion described above is in vivo. An alternative is the change of coding in vitro translation experiments. This requires the depletion of all tRNAs and the selective reintroduction of certain aminoacylated-tRNAs, some chemically aminoacylated.

{\displaystyle {\bar {a}}=\alpha a~;~~{\bar {c}}:=\alpha c~;~~{\bar {d}}:=\alpha ^{2}Rd~;~~\alpha :=\left({\frac {4E^{*}}{3\pi \Delta \gamma R^{2}}}\right)^{\frac {1}{3}}~;~~{\bar {A}}:=\pi c^{2}~;~~{\bar {F}}={\frac {F}{\pi \Delta \gamma R}}}

== Research == Paul Kaesberg's research had major impacts on the fields of biochemistry and virology. Some of his most influential research involved bacteriophage morphology, mosaic viruses, and X-ray scattering.

Sources: en.wikipedia.org

Supporting material

== Relationship with humans == The chain catshark is not currently fished for human consumption. The chain catshark has been described as "gorgeous", and this, combined with its small size, makes it a popular cold-water aquarium fish. It is frequently displayed and bred at public aquariums. Research in shark behavior, including reproduction, has been done in chain catsharks kept in public aquariums or laboratories.

=== Other lawsuits, investigations, and prosecutions === In August 2019, Schmitt withdrew a legal brief that argued that the First Amendment allowed government officials to withhold records from a freedom of information request, following criticism from transparency advocates who noted that the brief did not cite any case law. A Freedom Center of Missouri representative raised concern that the argument is similar to a case involving Governor Mike Parson, which Schmitt had not yet ruled on. Under Schmitt, the attorney general's office sued the city of Marshfield, Missouri, alleging that it maintained a ticket-quota system, in violation of the state law Schmitt had sponsored as state senator banning such quotas. In 2020, the suit ended in a settlement in which the city agreed to maintain a compliance program and have its state officials undergo training on the law. In September 2019, a bipartisan group of state attorneys general, including Schmitt, launched an antitrust investigation against Google. The attorneys general accused Google of prioritizing searches for companies that advertise on the search engine platform in violation of antitrust law.

The chemical composition of the electronic cigarette aerosol varies across and within manufacturers. Limited data exists regarding their chemistry. However, researchers at Johns Hopkins University analyzed the vape clouds of popular brands such as Juul and Vuse, and found "nearly 2,000 chemicals, the vast majority of which are unidentified." The aerosol of e-cigarettes is generated when the e-liquid comes in contact with a coil heated to a temperature of roughly 100–250 °C (212–482 °F) within a chamber, which is thought to cause pyrolysis of the e-liquid and could also lead to decomposition of other liquid ingredients. The aerosol (mist) produced by an e-cigarette is commonly but inaccurately called vapor. E-cigarettes simulate the action of smoking, but without tobacco combustion. The e-cigarette aerosol looks like cigarette smoke to some extent. E-cigarettes do not produce aerosol between puffs. The e-cigarette aerosol usually contains propylene glycol, glycerin, nicotine, flavors, aroma transporters, and other substances. The levels of nicotine, tobacco-specific nitrosamines (TSNAs), aldehydes, metals, volatile organic compounds (VOCs), flavors, and tobacco alkaloids in e-cigarette aerosols vary greatly. The yield of chemicals found in the e-cigarette aerosol varies depending on, several factors, including the e-liquid contents, puffing rate, and the battery voltage. Metal parts of e-cigarettes in contact with the e-liquid can contaminate it with metals. Heavy metals and metal nanoparticles have been found in tiny amounts in the e-cigarette aerosol.

The agreement specified that this agreement was only with Amat-Mamu, and no other person could lay claim to Belessunu's estate by providing for her. Two years after the agreement was made, two of Belessunu's cousins and fellow nadītus—Amat-Šamaš and Nīši-īnīšu—laid claim to the fields. The mayor of Sippar, Zimri-Erah, ruled that the inheritance was rightfully Belessunu's. The cousins were penalized for making a false claim over property, and they were forced to give Amat-Mamu a tablet that relinquished their claims. Professor Rivkah Harris speculated that Belessunu passed over her cousins in favor of Amat-Mamu because Amat-Mamu was a member of a wealthy family and therefore better able to support Belessunu during her life.

Sources: en.wikipedia.org

Frequently asked questions

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

What do researchers measure after administering the peptide?

Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.

Are the clinical effects well established?

Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network